Overview

Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of radical chemoradiotherapy plus oral capecitabine/teggio for 1 year in patients with N3.
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Cancer Hospital
Collaborators:
Jiangxi Provincial Cancer Hospital
Zhejiang Cancer Hospital
Treatments:
Capecitabine